Internal Reference Number: FOI_6478
Date Request Received: 17/02/2022 00:00:00
Date Request Replied To: 09/03/2022 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer Medication
Request Category: Researcher
| Question Number 1: In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with: 鈥� Afatinib 鈥� Alectinib 鈥� Atezolizumab monotherapy 鈥� Atezolizumab with chemotherapy 鈥� Bevacizumab 鈥� Brigatinib 鈥� Ceritinib 鈥� Crizotinib 鈥� Dacomitinib 鈥� Dabrafenib with Trametinib 鈥� Docetaxel monotherapy or combination with Carboplatin/Cisplatin 鈥� Durvalumab 鈥� Erlotinib 鈥� Gefitinib 鈥� Gemcitabine 鈥� Lorlatinib 鈥� Nintedanib with Docetaxel 鈥� Nivolumab 鈥� Osimertinib 鈥� Paclitaxel 鈥� Pembrolizumab monotherapy 鈥� Pembrolizumab with chemotherapy 鈥� Pemetrexed with Carboplatin/Cisplatin 鈥� Tepotinib 鈥� Vinorelbine with Carboplatin/Cisplatin 鈥� Any other active systemic anti-cancer therapy (SACT) 鈥� Palliative care only | |
| Answer To Question 1: Afatinib 0 Alectinib <5 Atezolizumab mono <5 Zero each for atezolizumab with chemo, bevacizumab, brigatinib, ceritinib Crizotinib <5 Zero each for dacomitinib, dabarfenib with trametinib, docetaxel mono or combination Durvalumab <5 Erlotinib 0 Gefitinib <5 Gemcitabine 0 Lorlatinib <5 Nintedanib with docetaxel 0 Nivolumab 0 Osimertinib 10 Paclitaxel 0 Pembrolizumab mono 11 Pembrolizumab with chemo <5 Pemetrexed with carb/cisplatin <5 Tepotinib 0 Vinorelbine with carb/cisplatin <5 Other SACT 7 Unable to answer about palliative care only | |
| Question Number 2: In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs: 鈥� Atezolizumab monotherapy 鈥� Atezolizumab with chemotherapy 鈥� Durvalumab 鈥� Gemcitabine 鈥� Nivolumab 鈥� Osimertinib 鈥� Paclitaxel 鈥� Pembrolizumab (Keytruda) Mono 鈥� Pembrolizumab (Keytruda) with Chemotherapy 鈥� Other active systemic anti-cancer therapy (SACT) 鈥� Palliative care only | |
| Answer To Question 2: Atezolizumab mono 0 Atezolizumab with chemo <5 Durvalumab <5 Zero each Gemcitabine , nivolumab, osimertinib, paclitaxel, pembrolizumab with chemo Pembrolizumab mono <5 Other SACT 0 Palliative only unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
